mHealth + e-Navigator for Medication Adherence
(Project STEP Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial seeks better methods to help Latino men who have sex with men and live with HIV adhere to their antiretroviral therapy (ART). It tests two strategies: one involves a program called TXTXT, which sends supportive text messages, and the other includes e-Navigation, a remote guidance system. Participants who do not respond well may receive additional support. Eligible participants should be Latino or Hispanic, identify as male, have HIV, and have experienced difficulty adhering to their medication in the past. They must also own a cell phone and use text messaging. As an unphased trial, this study provides a unique opportunity to contribute to research that could enhance support systems for others facing similar challenges.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, since the study focuses on improving adherence to ART (antiretroviral therapy), it is likely that you will continue your current ART regimen.
What prior data suggests that these interventions are safe for improving ART adherence?
Research shows that the TXTXT program, which sends text message reminders to help people take their medication, is generally safe. Although specific safety data is not available, TXTXT is a mobile health tool that sends messages to phones. This method is non-invasive, as it does not involve medical procedures or entering the body.
When combined with e-Navigation, these tools effectively help people manage their medication. E-Navigation typically includes remote support from a healthcare provider or counselor, which is also considered safe and well-tolerated.
Adding EMA (Ecological Momentary Assessment) to TXTXT and e-Navigation involves collecting feedback from participants throughout the day. This approach provides personalized support based on individual needs. Like the other methods, it is non-invasive and has been used in other studies without major safety issues.
Overall, these digital tools are non-invasive and aim to help people maintain their medication schedules. Research has not reported any significant negative side effects from using these methods.12345Why are researchers excited about this trial?
Researchers are excited about the mHealth + e-Navigator protocol because it aims to tackle medication adherence in a novel way. Unlike traditional approaches that might focus solely on patient education or reminders, this protocol uses digital interventions, like TXTXT and e-Navigation, to actively engage patients. By tailoring support based on adherence levels and using electronic tools, it offers a dynamic and personalized way to help patients stick to their medication regimen. This approach not only leverages technology but also provides flexibility, potentially leading to better long-term health outcomes for patients.
What evidence suggests that this trial's treatments could be effective for improving ART adherence among Latino MSM with HIV?
Studies have shown that text message reminders can help people with HIV adhere to their medication schedules. Specifically, tools like TXTXT, which sends regular reminders, have been linked to improved medication habits. In this trial, participants in Arm 1 will use TXTXT only, while those in Arm 2 will use both TXTXT and e-Navigation. Research suggests that combining TXTXT with e-Navigation, which provides additional support, can enhance these results. This combination has helped people take their medication consistently and maintain viral control. For some participants in Arm 2, adding EMA (ecological momentary assessment), which offers real-time feedback, can provide further support and improve medication habits. Overall, these strategies have shown promise in helping people with HIV adhere to their medication plans effectively.16789
Who Is on the Research Team?
Diana M Sheehan, Ph.D, M.P.H
Principal Investigator
Florida International University
Are You a Good Fit for This Trial?
This trial is for adult Latino men who have sex with men (MSM) and are living with HIV. Participants should be currently on antiretroviral therapy (ART) but may struggle with taking their medication consistently.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive TXTXT or TXTXT + e-Navigation for 6 months, with potential adjustments based on adherence
Follow-up
Participants are monitored for ART adherence and viral suppression after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Ecological Momentary Assessment (EMA) supported e-Navigation
- e-Navigation
- TXTXT
Find a Clinic Near You
Who Is Running the Clinical Trial?
Florida International University
Lead Sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Collaborator
Care Resource Community Health Centers
Collaborator
Care Resource Community Health Centers, Inc.
Collaborator